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Glaucoma
Intervals between Visual Field Tests When Monitoring the
Glaucomatous Patient: Wait-and-See Approach
David P. Crabb1 and David F. Garway-Heath2
PURPOSE. Published recommendations suggest three visual field
(VF) tests per year are required to identify rapid progression in
a newly diagnosed glaucomatous patient over 2 years. This
report aims to determine if identification of progression would
be improved by clustering tests at the beginning and end of the
2-year period.
METHODS. Computer-simulated ‘‘patients’’ were given a rapid
VF (mean deviation [MD]) loss of -2 dB/year with added MD
measurement variability. Linear regression of MD against time
was used to estimate progression. One group of ‘‘patients’’ was
measured every 6 months, another every 4 months, whereas
the wait-and-see group were measured either 2 or 3 times at
both baseline and at the end of a 2-year period. Stable
‘‘patients’’ (0 dB/year) were generated to examine the effect of
the follow-up patterns on false-positive (FP) progression
identification.
RESULTS. By 2 years, 58% and 82% of rapidly progressing
patients were correctly detected using evenly spaced 6- and 4-
month VFs, respectively. This power of detection significantly
improved to 62% and 95% with the wait-and-see approach (P <
0.001). When compared with evenly spaced VFs, the rate of
MD loss was better estimated by the wait-and-see approach,
but average detection time was slightly slower. Evenly spaced
testing incurred a significantly higher FP rate: up to 5.9%
compared with only 0.4% in wait-and-see (P < 0.001).
CONCLUSIONS. Compared with an evenly spaced follow-up, wait-
and-see identifies more ‘‘patients’’ with rapid VF progression
with fewer FPs, making it particularly applicable to clinical
trials. Modeling experiments, as reported here, are useful for
investigating and optimizing follow-up schemes. (Invest
Ophthalmol Vis Sci. 2012;53:2770–2776) DOI:10.1167/
iovs.12-9476
Accurately determining visual field (VF) progression inglaucoma is important: it is central to effective clinical
management of the disease, and it is the relevant functional
endpoint for clinical trials of new treatments. Monitoring VF
status in the patient is done by testing over a period of time.
Appropriate analysis to measure VF progression then requires a
sound comprehension of the amount or rate of VF loss
(decibels [dB] per year), the period of observation, the effect of
VF measurement variability, and the number of follow-up tests
required to detect change with adequate statistical power.1
The last of these is often overlooked. VFs can exhibit extensive
measurement error and it is widely accepted that clinical
management decisions made on results from one or two tests
will as a rule be unsound. A sufficient observation period and
an adequate number of VFs are required before change can be
documented with confidence. Furthermore, longitudinal stud-
ies2–4 and snippets of natural history data5,6 indicate there is
significant between-patient variability in the rate of VF
progression. Rates of VF loss in individuals cannot be well
predicted with knowledge about the patient at diagnosis, but
might be best estimated by collecting VFs over a period of
time. In a newly diagnosed patient the ideal would be to obtain
an adequate number of reliable examinations over a period of
time to exclude, or to detect, the presence of rapid VF
progression, thus offering the chance of intensifying treatment
to control the disease process in those patients that need it.
Until recently there has been little research evidence to offer
guidance concerning how frequently VF tests should be done
to optimally detect progression or best estimate the rate of
loss. There is certainly a need for an evidence base for this
issue because the scheduling of VFs in routine clinical practice
is often erratic and not well planned.7
Chauhan and colleagues (2008) published useful practical
recommendations for measuring rates of VF change in
glaucoma based on statistical power calculations.8 Central to
their report was the important principle that a sufficient
number of tests must be performed in a specified period to
give any chance of separating true disease progression from the
measurement variability inherent in the VF data. This sensible
conclusion is analogous to the accepted idea that a clinical trial
will not be sufficiently powered to detect an experimental
effect if an insufficient number of patients is recruited. One
specific result from the report suggested that newly diagnosed
patients should be tested with standard automated perimetry
(SAP) three times per year during the first 2 years after
diagnosis. By using this approach, rapidly progressing eyes,
losing average VF sensitivity (mean deviation [MD]) of more
than 2 dB per year, will be indentified with greater certainty
than if less frequent testing is performed. These recommen-
dations have subsequently been adopted as guidelines by the
European Glaucoma Society in their advice on patient
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examination and, therefore, have had an impact on glaucoma
management policy.9 The notion that three tests per year
should be performed to adequately measure visual progression
is also supported by evidence from previous studies using
computer simulation10 and retrospective examination of a
large VF data set.11
Some attention has been given to the prudent idea of
varying the intervals between VF tests to optimize detection of
progression.12 In one novel approach, the length of the interval
between subsequent tests depends on the outcome of previous
test results.13 Other alternatives to following a patient at evenly
spaced intervals, such as every 6 months or annually, have also
been suggested as a way of optimizing detection rates in
clinical trials.14 This report aims to determine whether
estimates of progression, and rate of VF loss, would be
improved if examinations were clustered at the beginning
(baseline) and end of a predetermined observation period. The
concept is motivated in part by well-established statistical
theory on design of experiments for optimal slope estimation
in linear regression.15,16 In practice, the idea here is to set a
follow-up period and then wait and see. This study, therefore,
examines the hypothesis, using data from computer simula-
tions, that wait and see offers advantages over evenly spaced
test intervals in detecting progression. The report also aims to
highlight the usefulness of this type of experiment (computer
simulation) as a way of exploring how best to optimize the use
of VFs when attempting to best detect progression in glaucoma
and best identify, by way of improved estimates of rate of
change, those patients that may or may not require intensified
treatment.
METHODS
In the computer simulations used in this study a VF was represented by
a single number, equivalent to a VF mean deviation (MD). Change in
MD is conventionally used as a marker for progression both in the
clinic and in clinical trials; it is a summary measure of the overall
reduction in VF sensitivity relative to a group of healthy age-matched
observers. The follow-up period for all the simulation experiments was
fixed to be 2 years. At baseline the VF was assumed to have an early to
moderate glaucomatous defect with an MD value of -4 dB. For stable
eyes, the true underlying MD was assumed to remain constant at -4 dB
at every visit over the 2-year follow-up period. For progressing eyes, a 2
dB per year rate of loss was given to the MD, meaning that the MD
rapidly deteriorates to -8 dB in a noise-free VF at the end of the follow-
up period (Fig. 1A).
The next key step in the simulation was to add measurement
variability to these true underlying values. Using the distribution of
standard deviations (SDs) of MD from glaucomatous patients in a large
longitudinal study,17 Chauhan et al. (2008) defined patients exhibiting
‘‘moderate’’ measurement variability to have SD of MD of 1 dB.8 For
simplicity, this level of variability (SD¼ 1 dB) was adopted throughout
all the simulation experiments, with a modification for progressing
eyes. Variability was added to the MD recorded at each follow-up visit
as a single number randomly sampled from a Normal distribution with
mean 0 dB and SD of x dB. For stable eyes, x was fixed at 1 dB; for
progressing eyes, x was modified to increase as MD worsens to mimic
the real situation where VF measurement variability increases as the VF
deteriorates.18 There are few examples in the literature quantifying
exactly how the SD of MD increases as the MD in an individual worsens.
One study,19 using frequency-of-seeing (FOS) data collected in patients,
indicated that response variability, albeit at individual VF locations
rather than MD, was reasonably well represented by the function, loge
(SD)¼A · sensitivity(dB)þB, where the constants A and B are -0.081
and 3.27, respectively. So, since our simulation assumed that the initial
VF has an MD of approximately -4 dB then the sensitivity values across
the VF will be, on average, approximately 26 dB. A progression rate of 2
dB loss per year will give an MD of -8 dB after 2 years, meaning that
the sensitivity values across the VF will be, on average in our example
eye, approximately 22 dB. By substituting these two values (26 and 22
dB) into the equation, and then subtracting one result from the other,
an estimate of the increase in SD of the sensitivity at a single
deteriorating location is yielded (1.23 dB). The variability at a VF test
location will naturally be higher than that in a summary measure such
as MD So, following simple statistical sampling theory, this value of 1.23
dB was then divided by the square root of the number of locations in a
typical VF (n» 50) to give an estimate of the expected increase in SD of
the MD over the 2-year period at this approximate level of VF defect
severity; this gave a value of 0.2 dB when rounded to one decimal
place. Consequently, for the progressing eyes the model fixed the SD of
MD at 0.9 dB at baseline and 1.1 dB at 2 years, with every 1 dB of loss in
MD accompanied by a 0.05-dB addition to the SD of MD In this way the
measurement variability in the simulation still assumes an average SD of
MD of 1 dB, allowing useful comparison with the results from Chauhan
et al. (2008),8 but it also accommodates the characteristic of VF
variability increasing over the follow-up period, as would be expected
with real data from a progressing eye (Fig. 1B).
Four different follow-up schemes (timing of VF examinations) were
investigated and were defined as: (1) 2 VF per year: evenly spaced. This
follow-up scheme involves a ‘‘patient’’ being tested twice a year with
evenly spaced, regular visits to the ‘‘clinic,’’ requiring 5 VFs in total
with one test at 0 (baseline), 6, 12, 18, and 24 months. (2) 2 VF: Wait
and see. This follow-up scheme involves a ‘‘patient’’ taking two tests at
baseline and two tests at 24 months, requiring only 4 VFs in total. (3) 3
VF per year: evenly spaced. This follow-up scheme involves a ‘‘patient’’
being tested three times per year with evenly spaced regular ‘‘visits’’ to
the ‘‘clinic,’’ requiring 7 VFs in total with one test at 0 (baseline), 4, 8,
12, 16, 20, and 24 months. (4) 3 VF: Wait and see. This follow-up
scheme involves a ‘‘patient’’ taking three tests at baseline and three
tests at 24 months, requiring 6 VFs in total.
For each of the four follow-up schemes, 10,000 different series of
stable eyes (0 dB per year) and 10,000 different series of rapidly
progressing eyes (2 dB per year) were simulated, with measurement
variability added as described.
Linear regression of MD, giving estimated rates of loss (dB per year),
was performed on each and every individual series. Eyes were classified
as ‘‘progressing’’ if they satisfied standard criteria of a slope (rate of loss)
of-1 dB or worse per year at the 5% level of statistical significance. Eyes
not satisfying these criteria were considered stable. The proportion of
‘‘progressing’’ eyes fulfilling the criteria in the simulated progressing
series gave an estimate of the power of the follow-up scheme (true-
positive rate). In turn, eyes classified as ‘‘progressing’’ in the simulated
stable series were defined as false-positive (FP) progression. With the
evenly spaced follow-up interval schemes, linear regression was applied
sequentially from the fourth test onward, so that progression could be
detected at 18 or 24 months (or not at all) with the two tests per year
scheme, or could be detected at 12, 16, 20, or 24 months (or not at all)
with three tests per year scheme. Time to detection was therefore
recorded for each ‘‘patient.’’ This mimics the clinical scenario where VF
series are tested for progression at each visit with a new VF. However, in
both wait-and-see follow-up schemes progression could, of course, be
detected only at 24 months, or not at all (Figs. 1C, 1D).
Estimating the rate of loss in patients is widely accepted to be an
important part of the clinical management of glaucoma.1,8 Therefore,
the SD of all the 10,000 rates of loss estimates (slopes from linear
regression in dB/year) was also calculated for each follow-up scheme.
This acts as a measure of how well the rate of loss is estimated by the
various follow-up schemes. A smaller SD of these slopes would suggest
that the follow-up scheme is better for predicting true rate of loss.
All simulations and analyses were performed within the open-
source statistical programming environment R (R Development Core
Team, R: A Language and Environment for Statistical Computing, R
Foundation for Statistical Computing, Vienna, Austria, URL: http://
www.R-project.org, 2008). All the R code used for this simulation is
freely available from the authors.
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RESULTS
Summary statistics from the simulation experiments describe
the ‘‘effectiveness’’ of each follow-up scheme. First, power of
detection indicates how many rapidly progressing ‘‘patients’’
would be detected in the 2-year period and was calculated as
the percentage of progressors detected or flagged from all
10,000 progressing patients. The overall false-positive (FP) rate
for each follow-up scheme (% of 10,000 stable eyes falsely
classified as rapid progressors) indicates the proportion of
patients who would be wrongly diagnosed as rapid progressors
when they are in fact truly stable. The average time to
detection indicates how soon a rapidly progressing patient can
be identified; this was calculated as a median time to event,
including the censored values (those not detected in n ¼
10,000). These summary measures for the different follow-up
schemes are shown in the Table.
Unsurprisingly, the power of detection was better with 3
VFs per year (evenly spaced) as compared with 2 VFs a year
(evenly spaced), confirming the results previously reported in
theoretical power calculations.8 The wait-and-see follow-up
schemes offered significantly better power of detection,
coupled with better FP rates compared with the evenly spaced
follow-up schemes (test of two binomial proportions; P <
0.001). With 3 VFs per year, the evenly spaced follow-up
yielded a better average detection time (by 4 months, or one
follow-up visit) when compared with the equivalent wait-and-
see scheme (3 VFs). Yet the wait-and-see scheme correctly
identified considerably more rapidly progressing patients
(albeit at 24 months) and, by definition, requires one fewer
VF test, when compared with the evenly spaced follow-up. FP
rates were much better controlled with the wait-and-see
schemes, because testing for progression is done once only
(rather than after each VF test from the fourth onward) and the
errors around the slope estimates are smaller. For example, as
shown in the Table, with 3 VFs per year, the regular (evenly
spaced) follow-up scheme gave an FP rate approximately 16
times worse than that provided by wait and see.
FIGURE 1. This schematic illustrates the steps in the computer simulation of a rapidly progressing eye. In (A) the eye is given rapid VF progression
of -2 dB per year loss over a 2-year period (MD declines from -4 to -8 dB). The follow-up scheme is of regular, evenly spaced VF tests with 3 tests
per year (7 VFs in total). The VF grayscale series shows the loss in the measurement variability-free eye. In (B) measurement variability is added to
each observation, randomly sampled from a Normal distribution that centers on the true observation. The SD of this distribution increases as the VF
sensitivity declines. The VF grayscale shows the progressing eye with measurement variability added, and is equivalent to the VF series that the
clinician would observe; the VF is truly changing, but it is masked by measurement variability. In (C) the rate of loss is estimated using linear
regression on the observed MD value over time and can be compared directly to the true rate of 2 db loss per year. If linear regression flags this as
progressing (at least -1 dB per year at 5% statistical significance), then this series is declared a true positive result in the simulation. In (D) the
equivalent process is carried out for the wait-and-see follow-up scheme. Note this requires one fewer VF test and, in this case the estimated rate of
loss is closer to the true rate of loss than that observed with the evenly spaced follow-up (C).
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Figure 2 shows histograms of the rate of loss (slopes from
linear regression) for the n ¼ 10,000 rapidly progressing
patients generated for each of the four follow-up schemes.
Comparison of the spread of these histograms gives a relative
idea of how well the true rate of loss is estimated when using
the different follow-up schemes. The narrower the distribu-
tion, the better the follow-up scheme is at estimating the true
rate of loss. This can be quantified by the SD of these
distributions (Table; also given in Fig. 2). The distributions
were narrower and SD smaller for the wait-and-see follow-up
schemes when compared with the evenly spaced follow-up
schemes. True rates of loss were, therefore, better estimated
with wait and see and the differences were highly significant
(F-test of variances; P < 0.001).
DISCUSSION
The statistics from this simulation experiment benefit from an
illustrative discussion to aid clinical interpretation. Consider a
glaucoma clinic that has 20 newly diagnosed patients who will
progress rapidly in 2 years. Of course, at the point of diagnosis,
without any monitoring, it is impossible to accurately identify
such patients. If these patients are tested only twice a year,
then the results from this report indicate that only approxi-
mately 12 of the 20 would be detected as having rapid VF
progression (>2 dB per year loss) by 2 years of follow-up. If it
is assumed that the clinic has sufficient perimetry resources for
testing patients every 4 months (3 per year, evenly spaced)
then this would result in approximately 16 of the patients
being detected, a more acceptable figure for true positive
detection in return for more frequent testing. If, however, the
wait-and-see approach is adopted over the 2-year period, then
nearly all of the rapidly progressing patients (19 of 20) would
be detected at 2 years; an even better outcome than the evenly
spaced follow-up and, furthermore, with one fewer test per
patient. Now, it would be reasonable to assume that for every
single case of a rapidly progressing patient there might be
approximately 10 patients who are not rapidly progressing
with VF loss that is relatively stable under treatment. This
‘‘illustrative’’ estimate is realistic, given findings from longitu-
dinal and retrospective studies3,20–23 (Heijl A, et al. IOVS
2008;49:E-Abstract 1155). For our imaginary clinic, these 200
patients are subjected to the same test frequency on follow-up
as the rapidly progressing patients. The results of the
simulation indicate that approximately 12 (5.9%) of these
patients would be falsely detected as rapidly progressing if 3
VFs per year are used in an evenly spaced follow-up over the 2-
year period. Because there are far fewer patients with true
rapid progression on treatment as compared with relatively
stable patients, the high frequency of testing (3 per year)
would yield almost an equivalent number of correct (16 true
positives) and incorrect (12 false positives) clinical decisions in
the 2-year period. Arguments about the relative importance of
true positive versus false positive progression identification are
beyond this discussion, but these findings at least caution
against the idea that simply increasing VF testing will be
beneficial for all patients. The significant advantage of the wait-
and-see approach, where analysis of results is done at one
point in time, is false positive decisions are mainly averted.
According to results of the simulation, around 1 in approxi-
mately 250 stable subjects would be falsely classified as being a
patient with rapid progression when they are, in fact, stable
TABLE. Summary Statistics Describing the Effectiveness of Each Follow-up Scheme over the 2-Year Period
2 VF Per Year:
Evenly-spaced 2 VF: Wait and See
3 VF Per Year:
Evenly-spaced 3 VF: Wait and See
Power to detect (%)* 58% 62% 82% 95%
False positives (%)† 2.9% 0.5% 5.9% 0.4%
Median detection time in months (IQR) 24 (18 to >24) 24 (24 to >24) 20 (16 to 24) 24 (24 to 24)
Number of VF tests 5 4 7 6
SD of rates of loss (dB per year) 0.63 0.51 0.56 0.41
IQR, Inter-quartile range. The 95% confidence intervals for the estimates of power to detect and false-positive rate (using the binomial
distribution) based on n ¼ 10,000 runs in the simulation are all smaller than (*) 61% and (†) 60.5%, respectively. Therefore, all the estimates of
power to detect are significantly different and, in turn, the false-positive rates and SD of rates of loss for the wait-and-see schemes are significantly
better than those for the respective evenly spaced schemes (P < 0.001).
FIGURE 2. Histograms of the rates of loss (slopes from linear regression) for the n¼ 10,000 rapidly progressing patients generated for each of the
four follow-up schemes. The wait-and-see scheme (6 VFs in total) has the narrowest distribution (and smallest SD) providing the best estimates of
the true rate of loss. Note that even the wait-and-see scheme using just 4 VFs in total, estimates the rate of loss more efficiently (SD¼ 0.51) than the
evenly spaced follow-up using 7 VFs in total (SD¼ 0.56).
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under treatment. Adopting this approach would allow the
clinician to have much more certainty that the flagged patient
is actually rapidly changing, and can be more certain that this is
not a false alarm, where the patient may undergo an
unnecessary change in their treatment. Wait and see results
in only a small delay in detection compared with evenly spaced
follow-up; the results from this simulation indicate that the
delay would be, on average, only approximately one visit (4
months), a modest difference in clinical detection time,
especially given that one fewer VF test is required with wait
and see.
The results from this report underline the futility of doing
too few VF tests. For example, four or five VFs scheduled over
2 years will identify only approximately 6 of 10 rapidly
progressing patients; annual testing would be worse. This
result suggests that a real commitment should be made to do
adequate testing in newly diagnosed patients; doing the odd VF
test in every patient once or less per year is probably as bad as
not doing it at all. Perhaps the key is to stratify patients into
those that will benefit from more frequent testing or a certain
testing follow-up scheme. Risk profiling patients to identify
potentially fast progressors is difficult; risk factors for
progression have been published,24,25 but, as yet, there is no
validated ‘‘risk calculator’’ for progression of manifest glauco-
ma and the accuracy of prediction from baseline factors is
unknown. On the other hand, it is known that a major risk
factor for going blind from glaucoma is advanced visual field
loss at presentation.26 Given limited VF testing resources, the
clinician should attempt to identify patients at greatest risk of
rapid progression and concentrate resources on these patients.
All this needs to be done without falling below a safe frequency
of testing that would identify unexpected progression in
patients thought to be at low risk. Patients may also be
stratified according to their ability to provide consistent VF
measurements: for example, patients consistently returning
noisy VFs may need a longer observation period before change
or stability can be documented with confidence. This
information about individual patient VF variability could be
extracted from data from the ‘‘cluster’’ of tests that would be
available at the beginning of the wait-and-see scheme. Of
course, a prospective study in real patients would be needed to
examine the advantages and problems of doing a cluster of
tests over a few visits in terms of practicalities, patient
acceptability, and learning effects. It would, for example, be
interesting to examine the hypothesis that data might be more
reliable if collected over a shorter period; testing in clusters at
the beginning and end of a predetermined follow-up may
obviate the need to continually reacquaint patients with SAP
and may help to reduce the effect of long-term learning in VF
testing.27 Moreover, it might be reassuring for both patient and
clinician if the wait-and-see scheme included an ‘‘alarm’’ VF at
1 year, with action taken if this measurement is dramatically
worse than the baseline measures. This action would not
assume rapid progression has occurred, but would result in
acquiring confirmation VFs to maintain statistical power. Of
course, this idea has not been tested here; the benefits of this
adjustment, and others, would be best examined with further
simulations or in a prospective study.
The simulation results draw attention to the problem of FP
identification of VF progression, which has been shown to
increase substantially with frequent periodic testing. This
contradicts the perception that more frequent monitoring of
the patient is in keeping with better clinical management. It is
important not to make an FP diagnosis of progression in stable
glaucoma because of the risks, side effects, and costs of
unnecessary additional medical or surgical treatment. Reduc-
ing FP identification of disease progression in glaucoma
management would also reduce the incidence of multiple
medication changes: there is decent evidence that this may
itself cause poor medication compliance and subsequent
disease progression.28,29 The wait-and-see approach offers
more control over FP identification of rapid progression. This
result is supported by evidence from a recent study on real data
where test follow-up patterns were retrospectively modified in
a similar fashion to the wait-and-see approach.30
There are limitations and observations to note about the
results from this study. As with a previous report,8 the results
from this study relate only to the initial follow-up period for
newly diagnosed patients. Moreover, these results are applica-
ble only to VF testing, and not monitoring intraocular pressure
(IOP). To date, IOP is the only evidential modifiable risk factor
for disease progression. Therefore, IOP should still be moni-
tored periodically, especially just after diagnosis and instigation
of therapy, to ensure the patient has adequate IOP control and is
adhering with therapy. It would, of course, be wrong to take an
IOP measure (or measures) and send the patient away for 2
years. Another point, not tested in the computer simulations
presented in this report but discussed elsewhere,31 is to note
the length of the observation period, rather than the periodicity
of testing, which is critical to estimating the rate of loss with
adequate precision, especially when making predictions of the
course of disease in a particular patient.
Another observation about the results from this study is the
assumption made that the rate of loss is linear and monotonic,
rather than sudden or episodic. This is a reasonable assumption
and broadly in line with current thinking about VF deteriora-
tion in glaucoma,23 although there is no real evidence to
dismiss the idea that for some patients the VF declines
episodically or collapses in a short space of time. Nevertheless,
it is noteworthy that in the computer simulation run in this
study, if the 2 dB loss per year was assumed to be an ‘‘event’’ (a
4-dB episodic loss at some time point in 2 years) then the wait-
and-see approach would always capture it. Although not
formally tested here, this might not be the case with a regular
follow-up when using linear regression to detect change
because some observations at evenly spaced tests may have
been made before the event occurred.
True status in any clinical series of data is uncertain,
whereas in a modeled or computer-simulated series it is certain
and thousands of tests can be carried out. Nonetheless, the
accuracy and translation of the results are dependent on the
assumptions and ‘‘input’’ to the model. For example, the model
presented in this study considered only one level of
measurement variability and one rate of loss (rapid progres-
sion, defined as 2 dB loss per year). This choice was deliberate
to make the simulations simple to understand, accessible, and
comparable to previous publications. The variability chosen is
in line with expected ‘‘moderate’’ levels, but as shown
previously, detection and FP rates, for example, worsen in
those patients who demonstrate higher levels of measurement
variability.8 Yet looking at a range of patient variability, for
example, would not affect the general conclusion about wait
and see offering advantages over evenly spaced sequential
follow-up. The wait-and-see approach is particularly applicable
to clinical trials, where real gains in statistical power and
improvements in estimating rates of loss in the different arms
of the study could be made with no increase in resources. Such
gains could be important in reducing sample sizes and
numbers needed not to treat when a no treatment control
arm is planned.
Progression behavior in glaucoma varies enormously, with
some patients progressing rapidly to significant visual loss and
the majority having slow or immeasurable deterioration. The
heterogeneity of the disease behavior should be contrasted
with the seemingly relative uniformity of disease monitoring,
where almost all patients are reviewed at fixed intervals. So,
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one aim of this report, via highlighting an alternative paradigm
to testing at fixed intervals, is to stimulate others to investigate
best practice for the diet of testing that should be used on
newly diagnosed glaucomatous patients. This best use of
resources should be high on the research and public health
agenda because clinics strain under the numbers being
monitored for this chronic condition, especially as the
population age increases. For example, it has been estimated
that glaucoma follow-up accounts for over one million visits to
a clinic annually in the UK National Health Service alone.32
Computer modeling experiments, as illustrated in this report,
provide a very helpful first planning step before embarking on
expensive trials to determine how best to monitor patients.
There are other good examples of their use in modeling both
VF12,13,33–36 and structural measurements37,38 in glaucoma
over time.
In conclusion, this study demonstrates a follow-up scheme
for monitoring VF progression as an alternative to evenly
spaced examination intervals: wait and see will identify more
patients with rapid VF progression with fewer FPs and one
fewer VF. The concept of scheduling VF tests in this way is
particularly applicable to clinical trials where VF progression is
the functional marker for glaucomatous change. Computer
simulation or modeling experiments, as reported here, are very
useful for investigating and optimizing other follow-up
schemes, before taking on the required costly and difficult
prospective studies.
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